Fatema Alrashed

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 7

Top Topics

Combination Therapy

Systematic Review

Patients With Inflammatory Bowel Disease

Ulcerative Colitis

Top Venues

Healthcare (Basel, Switzerland)

Journal of clinical medicine

JGH open : an open access journal of gastroenterology and hepatology

This page only lists publications with an associated author ORCID identifier.

Publications

Mohammad Shehab, Fatema Alrashed, Munerah Alyaseen, Zainab Safar, Tunrayo Adekunle, Ahmad Alfadhli, Talat Bessissow
Immunogenicity of Hepatitis B Vaccination in Patients with Ulcerative Colitis on Infliximab Is Attenuated Compared to Those on 5-Aminosalicylic Acid Therapies: A Prospective Observational Study. Vaccines 12 (4) (2024)
Mohammad Shehab, Fatema Alrashed, Munerah Alyaseen, Zainab Safar, Tunrayo Adekunle, Ahmad Alfadhli, Talat Bessissow
Immunogenicity of Hepatitis B Vaccination in Patients with Ulcerative Colitis on Infliximab Is Attenuated Compared to Those on 5-Aminosalicylic Acid Therapies: A Prospective Observational Study. Vaccines 12 (4) (2024)
Fatema Alrashed, Najlaa Almutairi, Mohammad Shehab
The Role of Clinical Pharmacists in Improving Quality of Care in Patients with Inflammatory Bowel Disease: An Evaluation of Patients' and Physicians' Satisfaction. Healthcare (Basel, Switzerland) 10 (10) (2022)
Fatema Alrashed, Hajer Alasfour, Mohammad Shehab
Impact of biologics and small molecules for inflammatory bowel disease on COVID-19-related hospitalization and mortality: A systematic review and meta-analysis. JGH open : an open access journal of gastroenterology and hepatology 6 (4) (2022)
Mohammad Shehab, Fatema Alrashed, Valérie Heron, Sophie Restellini, Talat Bessissow
Comparative Efficacy of Biologic Therapies for Inducing Response and Remission in Fistulizing Crohn's Disease: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. Inflammatory bowel diseases (2022)
Mohammad Shehab, Fatema Alrashed, Ahmad Alfadhli
COVID-19 Vaccine Booster Dose Willingness among Patients with Inflammatory Bowel Disease on Infliximab and Vedolizumab: A Cross-Sectional Study. Vaccines 10 (8) (2022)
Mohammad Shehab, Mohamed Abu-Farha, Fatema Alrashed, Ahmad Alfadhli, Khazna Alotaibi, Abdullah Alsahli, Thangavel Alphonse Thanaraj, Arshad Channanath, Hamad Ali, Jehad Abubaker, Fahd Al-Mulla
Immunogenicity of BNT162b2 Vaccine in Patients with Inflammatory Bowel Disease on Infliximab Combination Therapy: A Multicenter Prospective Study. Journal of clinical medicine 10 (22) (2021)